= Emerging. More than 5 years before clinical availability. (9.82%)
= Expected to be clinically available in 1 to 4 years. (12.95%)
= Clinically available now. (22.77%)
MSACL 2018 EU : Kim

MSACL 2018 EU Abstract

Topic: Proteomics

Podium Presentation in the Ether on Thursday at 11:40 (Chair: Renee Ruhaak)

Clinical Analytical Assay for AFP-L3 Using Multiple Reaction Monitoring-Mass Spectrometry for Diagnosing Hepatocellular Carcinoma

Youngsoo Kim (Presenter)
Seoul National University College of Medicine

Presenter Bio(s): Current position (2002-present):

Professor, Department of Biomedical Sciences, Seoul National University College of Medicine, and Department of Biomedical Engineering, Seoul National University College of Medicine

9/1987 - 5/1992:
The University of Texas at Austin,Department of Chemistry and Biochemistry, Austin, Texas. Ph.D. in Chemistry and Biochemistry, 1992

2/1992 - 9/1994:
Postdoctoral associate, Yale University, Department of Molecular Biophysics and Biochemistry

Authors: Hyunsoo Kim (1), Areum Sohn (2), Injun Yeo (1), Su Jong Yu (3), Jung-Hwan Yoon (3), and Youngsoo Kim (1,2)
Departmets of (1) Biomedical Engineering, (2) Biomedical Sciences and (3) Internal Medicine, Seoul National University College of Medicine, Yongon-Dong, Seoul 110-799, Republic of Korea

Abstract

We have developed and validated an MRM-MS assay for quantifying AFP-L3 in human serum to diagnose early-stage hepatocellular carcinoma. LiBA, the current standard method, cannot measure AFP-L3 concentrations accurately due to its low sensitivity. We addressed this issue with immunoprecipitation in conjunction with fractionation with LCA lectin. Consequently, the MRM-MS assay identified hepatocellular carcinoma patients that were missed by LiBA. In addition, we validated this approach in accordance with several multinational guidelines such as FDA, EMA, and CLSI. Our results demonstrated that this assay is robust and immediately applicable in clinical practice.


Financial Disclosure

DescriptionY/NSource
Grantsno
Salaryno
Board Memberno
Stockno
Expensesno
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above:

no